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Abstract
Background—There is a paucity of data on the current management and outcomes of liver
directed therapy (LDT) in older patients presenting with stage IV colorectal cancer (CRC).
Objective—To evaluate treatment patterns and outcomes in use of LDT in the setting of
improved chemotherapy.
Methods—We used Cancer Registry and linked Medicare claims to identify patients ≥66
undergoing surgical resection of the primary tumor and chemotherapy after presenting with stage
IV CRC (2001–2007). LDT was defined as liver resection and/or ablative procedures.
Results—We identified 5,500 patients. LDT was used in 34.9% of patients; liver resection was
performed in 1,686 patients (30.7%) and locoregional therapy in 554 patients (10.1%), with 322
patients having both resection and ablation/embolization. Use of LDT was negatively associated
with increasing year of diagnosis (OR=0.96, 95% CI 0.93–0.99), age >85 (OR=0.61, 95% CI
0.45–0.82), and poor tumor differentiation (OR=0.73, 95% CI 0.64–0.83). LDT was associated
with improved survival (median 28.4 vs. 21.1 months, P<0.0001); however, survival improved for
all patients over time. We found a significant interaction between LDT and time period of
diagnosis and noted a greater survival improvement with LDT for those diagnosed in the late
(2005–2007) time period.
Conclusions—Older patients with stage IV CRC are experiencing improved survival over time
independent of age, comorbidity and use of LDT. Greater gains in survival are seen with LDT for
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patients diagnosed in the later time period. These data suggest that improved patient selection may
be positively impacting outcomes.
Keywords
metastatic colorectal cancer; liver directed therapy; synchronous lesions; colorectal cancer liver
metastases
INTRODUCTION
Metastatic disease is present at the time of diagnosis in 20% of patients presenting with
colorectal cancer, and for these patients, the liver is the most common site of metastatic
disease.1, 2 Advances in chemotherapeutic regimens, surgical technique, and postoperative
care have allowed for aggressive treatment of liver metastases in patients who previously
would have only been candidates for palliative chemotherapy. Liver resection is the only
potentially curative option and the preferred treatment modality in patients with isolated and
resectable liver metastases. However, resection may not be possible in the case of multiple
metastases, extensive bilobar disease, or in patients who are poor surgical candidates. When
resection is not possible, liver ablation or chemoembolization are alternative techniques to
decrease tumor burden and prolong survival.3 Treatment with aggressive multimodality
therapy has led to 5-year survival rates exceeding 50% for select patients.4
There is a paucity of data on the current management and outcomes in older patients
presenting with colorectal cancer liver metastases. In the setting of metastatic disease at
presentation, the management of liver metastases is especially challenging and the benefit of
liver directed therapy in the setting of modern chemotherapy is not as clear. While single
institution retrospective studies from specialized centers have demonstrated low mortality
rates in carefully selected older patients undergoing liver resection,5–12 these reports have
included both synchronous and metachronous disease. In addition, the effects of ablative
therapies such as radiofrequency ablation and chemoembolization on survival have not been
well studied.
We used population-based data to evaluate the use of liver resection, ablation, and
chemoembolization (liver directed therapy) in older patients presenting with metastatic
colorectal cancer (CRC) in the era of more effective oxaliplatin- and irinotecan-containing
chemotherapeutic regimens. 13–15 We specifically evaluated time trends in the use of these
modalities and, when employed, the timing of liver directed therapy in relation to treatment
of the primary tumor and receipt of systemic therapy. Finally, we evaluated the effects of
these therapies on long-term survival.
METHODS
This study was deemed to be exempt from review by the Institutional Review Board at the
University of Texas Medical Branch.
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We used Texas Cancer Registry (TCR)- and Surveillance Epidemiology and End Results
(SEER)-linked Medicare data from 2000–2009. SEER and TCR collect data on all cancer
cases covered by the respective registries. Data collected include patient demographics,
primary tumor site, stage, first course of treatment, tumor morphology, cause of death, and
survival.16, 17 All cancer-related variables included in the analysis were identical between
the two registries. The Center for Medicare and Medicaid Services performed the Medicare
linkage for both datasets. Approximately 98% of all people aged 65 and older in TCR and
93% in SEER can be linked with Medicare enrollment and claims files.18, 19 The Medicare
claims data include billing information on hospital stays, physician services, and hospital
outpatient visits.20 For this study, data were extracted from the Medicare Denominator file
(demographics and eligibility), the Medicare Provider Analysis and Review file (MEDPAR,
inpatient claims), the Carrier claim file (claims from non-institutional service providers), and
the Outpatient Standard Analytical File (OutSAF, claims from institutional outpatient
providers).20
Cohort Selection
We selected patients diagnosed with stage IV colon and rectal cancers and ICD-O-3
histology codes (Table 1) consistent with adenocarcinoma diagnosed between 2001 and
2007. We excluded patients who did not have Medicare Parts A and B coverage without
HMO for one-year prior and two years following diagnosis to allow for evaluation of
comorbidity in the year prior to diagnosis and to follow all patients for at least two years.
Follow-up was complete in both datasets through the end of 2009. Finally, we excluded
patients who did not undergo resection of the primary tumor and did not receive
chemotherapy at any point after diagnosis, as liver resection is generally not indicated if the
primary tumor is not optimally treated. Resection of the primary tumor and chemotherapy
were included if they occurred before or after liver directed therapy. 5,500 patients met our
inclusion criteria (Figure 1).
Resection of Primary Tumor, Chemotherapy, and Liver-Directed Therapy
Treatment of the primary tumor was defined as the receipt of chemotherapy and resection of
the primary tumor after a diagnosis of stage IV colorectal cancer. Definitive resection of the
primary tumor was identified from the Medicare claims (MEDPAR, carrier, outpatient SAF)
using International Classification of Diseases, Ninth Revision Clinical Modification (ICD-9-
CM) procedure codes and Current Procedural Terminology, Fourth Edition (CPT-4) codes
for colorectal resection (Table 1), including open and laparoscopic colon and rectal
resections, with or without colostomy.
As defined on the SEER-Medicare website, we used MEDPAR, carrier, and outpatient
claims to identify ICD-9, CPT/Healthcare Common Procedure Coding System (HCPCS)
codes, J codes, and revenue center codes for administration of chemotherapy.21 Specific
regimens were identified by J codes for specific agents (Table 1). “Standard” chemotherapy
was defined as 5-fluorouracil ± leucovorin. “Modern” chemotherapy was defined as any
regimen containing oxaliplatin or irinotecan. Use of bevacizumab was analyzed
independently. Patients were considered to have received chemotherapy if they had any of
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the codes listed in Table 1 at any point before or after surgical resection of the primary
tumor.
Medicare claims in inpatient, outpatient, and carrier files were examined for ICD-9 or CPT
procedure codes indicating receipt of liver directed therapy. Liver directed therapy was
defined as liver resection, liver ablation, or chemoembolization (Table 1). Few patients
underwent ablation or chemoembolization; therefore, these categories were combined as
“ablation/embolization” for all analyses.
Covariates
Patient characteristics included age, sex, race (white, black, Hispanic, other), and the
Klabunde modification of the Charlson comorbidity index (0, 1, 2, ≥3).22 Median income
and percent of residents with <12 years education were determined at the zip code level.
Tumor characteristics included type (colon vs. rectum), site (right, left, transverse, and
rectum), nodal status, and tumor differentiation. All patients had stage IV disease at the time
of diagnosis.
Statistical Analysis
We calculated summary statistics for the overall cohort and determined the percentage of
patients receiving liver directed therapy. Chi square tests were used to evaluate the
unadjusted associations between liver directed therapy and patient, tumor, and primary
treatment characteristics.
We used a Cochran-Armitage test for trend to evaluate trends in use of liver resection and
liver ablation/embolization procedures. Multivariable logistic regression was used to
determine factors independently associated with the receipt of liver directed therapy.
Kaplan-Meier disease-specific 5-year survival curves were generated from date of diagnosis
for patients in the following treatment groups: overall cohort, patients undergoing liver
directed therapy, and those not treated with liver directed therapy. Log rank tests were
performed to compare survival in patients treated with liver directed therapy vs. those not
treated with liver directed therapy. This analysis was also stratified by time period (early =
2001–2004 and late = 2005–2007). A Cox proportional hazards model was used to evaluate
the independent association between liver directed therapy and survival, as well as the
interaction between time period of diagnosis and liver directed therapy.
All p-values were from two-sided tests. All analyses were performed with SAS version 9.2
(SAS Inc., Cary, NC, USA). Statistical significance was accepted at the p<0.05 level.
RESULTS
Patient and tumor characteristics (Table 2)
We identified 5,500 patients who received chemotherapy and underwent resection of the
primary tumor (Figure 1). The mean age of the cohort was 74.3 ± 5.7 years. Women
comprised 50.2% of the study sample. The majority of patients were white and had a
Charlson comorbidity score of zero. The primary tumor was of colonic origin in 82.4% of
patients.
Vargas et al. Page 4























Per the selection criteria, all patients underwent surgical resection of the primary tumor and
received chemotherapy. Surgical resection was performed in an emergent setting in 20.2%
of patients. Modern oxaliplatin- or irinotecan-containing chemotherapy regimens were used
in 56.8% of patients. Standard chemotherapy (5-FU and leucovorin) was administered to
29.0% of patients. The remaining 14.2% of patients received other agents. Bevacizumab was
used in 27.9% of patients (Table 2).
Liver directed therapy, defined as liver resection or ablation/embolization, was performed in
1,918 (34.9%) patients. Liver resection was performed in 1,686 patients (30.7%). Liver
resection was performed in 1,686 patients over the course of the study period. Of these,
1,289 had one or more biopsy/wedge resection, 174 had one or more lobectomies, 108 had
one or more partial hepatectomies, and 115 had a combination of any of the procedures. Of
the 115 patients having more than one type of resection, 96 had a biopsy/wedge and either a
lobectomy or partial hepatectomy. The remaining 19 patients had lobectomy and partial
hepatectomy. Ablation/embolization was performed in 554 patients (10.1%). Of these
patients, 322 were treated with both resection and some form of ablation/embolization. Liver
resection rates were stable over time (31.0% in 2001 to 27.8% in 2007, P=NS, Figure 2) as
were rates of ablation/embolization (7.6% in 2001 to 10.9% in 2007, P=NS, Figure 2), but
the use of modern chemotherapy increased from 41.0% in 2001 to 77.3% in 2007, P<0.0001.
The mean time from diagnosis to liver directed therapy was 117 ± 217 days. Patients
undergoing liver resection underwent liver resection a mean of 83 ± 168 days after
diagnosis; whereas, patients undergoing ablation/embolization had a mean time of 390 ± 371
days between diagnosis and ablation or chemoembolization. Liver directed therapy was
performed at the time of resection of the primary tumor in 74.4%, after resection in 21.2%,
and before resection in 4.5%. In 76.0% of patients, liver directed therapy and resection of
the primary tumor were performed prior to administration of systemic chemotherapy. Liver
directed therapy and primary tumor resection were performed after chemotherapy in 7.4%
and chemotherapy was administered between primary tumor resection and liver directed
therapy in 16.6% of patients (Figure 3).
Factors associated with liver directed therapy
In a bivariate analysis (Table 2), younger age, receipt of modern chemotherapy, and use of
bevacizumab were associated with a higher likelihood of receiving liver directed therapy.
Patients treated with ablation/chemoembolization were more likely to be younger and have
colon primary tumors. In a multivariable model (Table 3) controlling for comorbidity and
socioeconomic status, there was a negative association between use of liver directed therapy
and increasing year of diagnosis (OR=0.96, 95% CI 0.93–0.99), age >85 (OR=0.61, 95% CI
0.45–0.82), and poor tumor differentiation (OR=0.73, 95% CI 0.64–0.83). The
administration of modern chemotherapy was more strongly associated with liver directed
therapy use than treatment with standard chemotherapeutic regimens (OR=1.44, 95% CI
1.25–1.66).
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Liver directed therapy and survival
The median disease-specific survival for the overall cohort was 23.4 months. When
stratified by treatment of liver metastases, the median survival was 28.4 months for patients
undergoing liver-directed therapy compared to 21.1 months in patients who did not receive
treatment for liver metastases (P<0.0001, Figure 4). However, survival improved for both
groups over time. When stratified by time period of diagnosis, there was an improvement in
median survival from 25.4 months in the early time period (2001-2004) to 35.9 months in
the late time period (2005–2007) in patients undergoing liver directed therapy (P<0.0001).
Similarly, for patients not treated with liver directed therapy, median survival improved
from 19.6 months to 23.4 months between the early and late time periods (P<0.0001, Figure
5).
In a Cox proportional hazards model, there was a significant interaction between receipt of
liver directed therapy and time period of diagnosis (P=0.04). Therefore, the analysis was
stratified by time period of diagnosis. Receipt of liver directed therapy in the later time
period was associated with a 25% decrease in the hazard of death compared to a 16%
decrease in the early time period (Table 4).
DISCUSSION
Our data demonstrate that survival has significantly improved over time in older patients
presenting with stage IV colorectal cancer. As expected, carefully selected patients treated
with chemotherapy, resection of the primary tumor, and liver directed therapy experienced
optimal 5-year disease-specific survival. However, our data suggest that many older patients
deemed to be appropriate candidates for resection of the primary tumor and receipt of
systemic chemotherapy did not receive liver directed therapy. All patients in this study
underwent resection of the primary tumor, implying a reasonable performance status. In
addition, the 40% five-year disease specific survival rate in the group not receiving liver
directed therapy indicates that a large proportion of these patients may have been adequate
candidates for liver directed therapy, both from the standpoint of operative risk and disease
burden.
Liver directed therapy use was stable over time in this older cohort with stage IV colorectal
cancer and resected primary tumors, with the majority of liver directed therapy in this age
group being wedge resections or minor liver procedures rather than formal lobectomies or
partial hepatectomies. In addition, survival improved over time, independent of receipt of
liver-directed therapy or modern chemotherapy. Younger age was one of three factors
independently associated with receipt of liver directed therapy, consistent with previous
studies demonstrating lower use of liver directed therapy, particularly liver resection, with
increasing age.23–25 In a population based study evaluating referral patterns in patients with
isolated colorectal cancer liver metastases, Ksienski et al. found that age was the most
common reason cited for non referral to a hepatobiliary surgeon.26 However, short-term and
long-term outcomes following liver resection in carefully selected older patients are no
different than in their younger counterparts.6–12, 27–29 Similarly, in patients ≥ 70 years old
not eligible for hepatic resection, the use of arterial embolization with or without
radiofrequency ablation has not been associated with worse short-term outcomes.30 With
Vargas et al. Page 6






















advances in chemotherapeutic regimens, our data suggest that early referral and optimal
selection of patients for liver directed therapy has the potential to further improve survival in
older patients presenting with advanced colorectal cancer.
Our data contribute to the existing literature illustrating a marked improvement in survival
over the last two decades for patients with stage IV colorectal cancer. Even after we
controlled for receipt of liver-directed therapy, time period of diagnosis was independently
associated with improved survival. Improvements in cancer survival over time have been
previously documented using SEER data by Sun et al.31 Likewise, using data from two
high-volume cancer referral centers and SEER data from 1990–2005 to confirm the trends,
Kopetz et al. observed a survival improvement for patients with metastatic colorectal cancer
over time. Survival for those diagnosed after 2004 was temporally related to the adoption of
newer chemotherapeutic agents.32 The value of newer chemotherapeutic agents has also
been observed in a previous population-based study.33 The gains in survival over time are
likely multi-factorial and attributable in part to the rapid adoption of modern
chemotherapeutic regimens, improvements in patient selection for surgery, and advances in
the management of tumor related complications.34 In addition, it is established that
colorectal cancer patients have improved survival when metastatic disease is identified early
in the course of illness. The use of computed tomography in the work up of patients with
colorectal cancer has proven to lead to the earlier detection of metastases and improved
survival and may also account for the improved survival seen over time.35–37
Our findings also support the concept that optimal selection for hepatic resection may
improve outcomes, which has been previously introduced in other population-based studies.
A retrospective review by Mala et al. validated a preoperative clinical risk score to select
patients who are most likely to benefit from hepatic resection of colorectal cancer
metastases.38 Patients undergoing hepatic resection for colorectal cancer liver metastases
were stratified into one of five clinical risk scores as defined by Fong et al.39 Survival
analysis of these patients demonstrated a statistically significant difference in survival for
patients with a clinical risk score of 0–2 compared to patients with a clinical risk score of 3–
4 (P=0.0006). Multiple subsequent studies have since validated the clinical risk score as a
viable tool to reduce postoperative morbidity and mortality through better patient
selection.40, 41 Another study further emphasized enhanced urgency in applying this
selection process specifically to older patients.6
Our study has several limitations. Using observational data in cancer patients, there is a
significant likelihood for selection bias in comparing patients undergoing different treatment
regimens, especially when surgery is considered. Our cohort included only patients
receiving combined treatment for colorectal cancer metastatic to the liver, making them a
highly selected group of patients. These patients likely had a higher functional status, were
fit enough to tolerate aggressive cancer treatment, and their extent of metastatic disease was
likely limited when compared to other patients with stage IV colorectal cancer. As a result,
the validity of our study is limited to these patients only, and care should be taken when
extrapolating these results to all colorectal cancer patients with synchronous liver
metastases. Although patients who underwent liver directed therapy likely had a lower
burden of disease, we are unable to assess the extent of disease present using administrative
Vargas et al. Page 7






















data. Nonetheless, we observed a survival improvement over time for all patients
independent of treatment of liver metastases.
Older patients with stage IV CRC are experiencing improved survival over time independent
of age, comorbidity, and use of liver directed therapy. However, many older patients deemed
to be appropriate candidates for resection of the primary tumor and receipt of systemic
chemotherapy are not receiving liver directed therapy. Improved patient selection and earlier
detection of metastatic disease may be positively impacting outcomes. Early referral and
optimal selection of patients for liver directed therapy has the potential to further improve
survival in older patients presenting with advanced colorectal cancer. Patients presenting
with stage IV colorectal cancer should be treated by a multi-disciplinary team approach and
practitioners should continue to incorporate patient and tumor factors in the selection criteria
for treatment of liver metastases.
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Cohort selection. TCR- and SEER-Medicare linked data for patients presenting with stage
IV colorectal cancer. Patients who did not have Medicare Parts A and B coverage without
HMO for one-year prior and two years following diagnosis were excluded. Only patients
undergoing resection of the primary tumor and chemotherapy were included. The final
cohort included 5,500 patients.
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Time trends in use of liver directed therapy. Rates of liver directed therapy remained stable
over time (34.1% in 2001 vs. 33.4% in 2007, P=NS).
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Timing of liver directed therapy in relation to treatment of the primary tumor in patients
undergoing treatment of liver metastases. A) Timing of liver directed therapy relative to
resection of the primary tumor. 74.4% of patients underwent liver directed therapy at the
time of primary tumor resection. B) Timing of chemotherapy relative to resection of the
primary tumor and liver directed therapy. 76.0% of patients received chemotherapy as the
initial treatment modality. 16.6% of patients received chemotherapy between resection of
the primary tumor and liver directed therapy.
Vargas et al. Page 13























Kaplan-Meier analysis of the five-year disease specific survival for patients treated with
resection of the primary tumor and chemotherapy stratified by receipt of liver directed
therapy. Median survival was 28.4 months for patients undergoing liver-directed therapy
compared to 21.1 months in patients who did not receive treatment for liver metastases
(P<0.0001).
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Kaplan-Meier analysis of the five-year disease specific survival for patients treated with
resection of the primary tumor and chemotherapy ± liver directed therapy, stratified by early
and late time periods. Median survival improved over time, from 25.4 months to 35.9
months in patients undergoing liver directed therapy (P<0.0001). Median survival also
improved for patients who did not receive liver directed therapy (19.6 months vs. 23.4
months, P<0.0001).
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Table 1
ICD-9 diagnosis codes used to identify colorectal cancer, treatment, and sites of metastatic disease in patients
presenting with stage IV colorectal cancer
Cancer ICD-O-3 histology codes
Adenocarcinoma 8000, 8050, 8051, 8052, 8010, 8021, 8022, 8140, 8141, 8143, 8145, 8147, 8210, 8211,
8220, 8221, 8230, 8260, 8261, 8262, 8263, 8430, 8440, 8470, 8471, 8480, 8481, 8490,
8550, 8551, 8570, 8571, 8572, 8573, 8574, and 8575
Treatment Procedure codes
Colorectal resections ICD-9-CM: 45.71–45.76, 45.79, 45.81- 45.83, 17.31–17.36, 17.39, 48.42–48.43, 48.49–
48.52, 48.59–48.64, 48.69
CPT: 44140–44141, 44143–44147, 44150- 44153, 44160, 44204–44208, 44210, 44155–
44158, 45110–45114, 45116, 45119- 45121, 45123, 45126, 45160, 45170, 45171, 45172,
44120–44212, 45395, 45397
Chemotherapy ICD-9 procedure code: 99.25
ICD-9 diagnosis codes: v58.1, v66.2, and v67.2
HCPCS and CPT codes: Q0083-Q0085, 51720, J0640, 964XX, 96400–96549, J9000-
J9999, G0355-G0363, G9021- G9032
Modern chemotherapy (oxaliplatin, irinotecan,
or bevacizumab containing regimens)
J9263, J9206, and J9035
Standard chemotherapy (5FU/LV only) J9190 and J0640
Liver resections CPT: 47100, 47120, 47122, 47125, 47130
ICD-9 codes: 50.12, 50.2, 50.22, 50.3
Ablation/embolization liver procedures CPT: 47370 (RFA), 47371 (cryosurgical), 47380 (open RFA), 47381 (open cryosurgical),
47382 (percutaneous RFA)
ICD-9: 50.2, 50.23–50.26, 50.29
Liver chemoembolization CPT: 37204 and 75894
ICD-9: 50.93–50.94
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Table 4
Cox models for five-year disease specific survival for the overall cohort, in the early time period (2001–2004)
and late time period (2005–2007).
Factor (REF) Overall cohort 2001–2004 HR (95% CI) 2005–2007 HR (95% CI)
Treatment (- LDT) 0.82 (0.76–0.88) 0.84 (0.77–0.91) 0.75 (0.66–0.86)
Time period (2001–2004) 0.68 (0.63–0.73) NA NA
Age (66–69 yrs)
 70–74 yrs 1.13 (1.03–1.24) 1.09 (0.97–1.22) 1.20 (1.02–1.41)
 75–79 yrs 1.23 (1.12–1.36) 1.20 (1.07–1.35) 1.28 (1.08–1.52)
 80–84 yrs 1.40 (1.25–1.56) 1.37 (1.20–1.57) 1.46 (1.21–1.78)
 ≥ 85 yrs 1.66 (1.42–1.95) 1.80 (1.48–2.18) 1.35 (1.01–1.80)
Sex (Female) 0.97 (0.91–1.03) 0.93 (0.86–1.00) 1.07 (0.95–1.20)
Race (White)
 Black 1.09 (0.97–1.23) 1.07 (0.93–1.24) 1.14 (0.92–1.41)
 Hispanic 0.88 (0.69–1.12) 0.91 (0.69–1.20) 0.79 (0.47–1.32)
 Other 0.94 (0.80–1.10) 0.94 (0.77–1.15) 0.94 (0.71–1.24)
Cancer (Rectum) 1.21 (1.11–1.33) 1.17 (1.05–1.30) 1.35 (1.15–1.59)
Poorly differentiated (No) 1.37 (1.27–1.47) 1.33 (1.22–1.45) 1.45 (1.28–1.65)
Charlson Comorbidity (0)
 1 1.01 (0.94–1.09) 1.00 (0.91–1.10) 1.00 (0.87–1.15)
 2 1.15 (1.02–1.30) 1.14 (0.98–1.32) 1.18 (0.96–1.47)
 ≥ 3 1.10 (0.92–1.30) 1.34 (1.08–1.66) 0.81 (0.61–1.08)
Node status (Positive)
 Negative 0.52 (0.47–0.57) 0.51 (0.46–0.57) 0.55 (0.46–0.66)
 Unknown 0.99 (0.88–1.11) 0.96 (0.84–1.11) 1.05 (0.86–1.28)
Income (Q1)
 Q2 1.08 (0.98–1.19) 1.05 (0.93–1.18) 1.11 (0.93–1.31)
 Q3 1.02 (0.92–1.12) 1.01 (0.90–1.14) 1.02 (0.86–1.21)
 Q4 0.93 (0.84–1.02) 0.94 (0.83–1.05) 0.90 (0.75–1.07)
Chemotherapy (Standard)
 Modern 1.13 (1.04–1.22) 1.26 (1.15–1.37) 0.81 (0.68–0.95)
 Other 1.27 (1.15–1.41) 1.22 (0.07–1.38) 1.23 (1.00–1.51)
Interaction between time period and receipt of liver directed therapy P=0.04
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